Ferring Pharmaceuticals Announces Grand Opening of US Operations Center
Ferring Pharmaceuticals has expanded its footprint in New Jersey with the opening of its new US Operations Center on a 25-acre lot located at 100 Interpace Parkway in Parsippany. Instead of relocating its outsourcing manufacturing to other states or overseas, Ferring’s new center is a sign of the company’s continued commitment to New Jersey and bringing new jobs to the local community.
The facility recently completed the integration of staff into the state-of-the-art manufacturing suite and product development laboratories. The US Operations Center will house 275 employees across management, administration, commercial operations, manufacturing and R&D, a set up designed to allow unique opportunities for collaboration across various operational disciplines. Ferring plans to expand that number significantly as the manufacturing facility gradually comes online over the course of the next 18–24 months.
“This is just the start of an exciting journey of growth to come,” said Michel Pettigrew, CEO, Ferring Holding Inc. and President of the Executive Board and Chief Operating Officer, Ferring Group. “We hope this new operations center stands as a symbol of our philosophy as a company — a place where our commitment to the science and to our patients is front and center; a learning environment where employees are encouraged to take initiative and stretch beyond their designated role; and a cornerstone of the community, dedicated to giving back.”
The facility allows the company to reinforce its commitment to New Jersey at a time when many pharmaceutical companies are making out-of-state moves. The approach is an example of Ferring’s dedication to the community it serves. Moreover, the move to stay in state provides access to experienced pharmaceutical talent and world class academic institutions. Notably, Ferring is also working with several organizations in New Jersey to offer open positions to veterans of the US armed forces.
“This grand opening serves as a reminder of our commitment to the US, New Jersey and to our long-term view on the science that can make a real difference in the lives of the patients we serve,” said Aaron Graff, President and COO Ferring Pharmaceuticals Inc. “As I watch our teams start to integrate into the new operations center, I already see the positive impact the space has on our ability to collaborate across functions within the organization and provide a premium workspace for our employees.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.